Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Ward

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
European Urology|January 22, 2014
Focal therapy in prostate cancer: international multidisciplinary consensus on trial designWillemien van den Bos, Berrend G Muller, Hashim Ahmed, et al.
Cancer|September 17, 2020
Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classificationsEric C Umbreit, Andrew G McIntosh, Chalairat Suk-Ouichai, et al.
Urologic Oncology|January 23, 2024
The association of body mass index with tumor aggression among men undergoing radical prostatectomyJustin R Gregg, Resa Magill, Andrew M Fang, et al.
The Oncologist|June 30, 2026
Divergent Biology and Outcomes of Somatic Transformations in Germ Cell TumorsZachariah Thomas, Andrew C Johns, Michael Glover, et al.
Nature Medicine|March 28, 2017
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerJianjun Gao, John F Ward, Curtis A Pettaway, et al.
Cancers|December 17, 2020
Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell TumorEric C Umbreit, Bilal A Siddiqui, Michael J Hwang, et al.
Oncotarget|November 19, 2016
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testisMehmet Asim Bilen, Kenneth R Hess, Matthew T Campbell, et al.
The Journal of Urology|February 9, 2026
Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort StudyTarek Lawen, Rebekka S Garcia, Matthew T Smith, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
BJU International|June 11, 2015
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillanceJohn W Davis, John F Ward, Curtis A Pettaway, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
European Urology|January 22, 2014
Focal therapy in prostate cancer: international multidisciplinary consensus on trial designWillemien van den Bos, Berrend G Muller, Hashim Ahmed, et al.
Cancer|September 17, 2020
Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classificationsEric C Umbreit, Andrew G McIntosh, Chalairat Suk-Ouichai, et al.
Urologic Oncology|January 23, 2024
The association of body mass index with tumor aggression among men undergoing radical prostatectomyJustin R Gregg, Resa Magill, Andrew M Fang, et al.
The Oncologist|June 30, 2026
Divergent Biology and Outcomes of Somatic Transformations in Germ Cell TumorsZachariah Thomas, Andrew C Johns, Michael Glover, et al.
Nature Medicine|March 28, 2017
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerJianjun Gao, John F Ward, Curtis A Pettaway, et al.
Cancers|December 17, 2020
Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell TumorEric C Umbreit, Bilal A Siddiqui, Michael J Hwang, et al.
Oncotarget|November 19, 2016
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testisMehmet Asim Bilen, Kenneth R Hess, Matthew T Campbell, et al.
The Journal of Urology|February 9, 2026
Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort StudyTarek Lawen, Rebekka S Garcia, Matthew T Smith, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
BJU International|June 11, 2015
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillanceJohn W Davis, John F Ward, Curtis A Pettaway, et al.
Pageof 11